Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 SPOTLIGHT Study of PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

− Results to be presented at American Urological Association’s 2023 Annual Meeting (AUA2023) –

Reno, Nevada (UroToday.com) -- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced the presentation of additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer, among a subgroup of patients who had undergone primary treatment with radiation therapy only. The results will be presented at the upcoming American Urological Association’s 2023 Annual Meeting (AUA2023), being held in Chicago, Ill., from April 28 to May 1, 2023. 18F-rhPSMA-7.3 is an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid (rh) PET imaging agent. The SPOTLIGHT trial (NCT04186845) was a Phase 3, multi-center, single-arm imaging study conducted in the United States and Europe to evaluate the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy. Currently, 18F-rhPSMA-7.3 is investigational and has not received regulatory approval.

Details of the presentation are listed below.

Date: Saturday, April 29, 2023
Presentation: 18F-rhPSMA-7.3 Detection Rates in Patients with Recurrence of Prostate Cancer Following Primary Treatment with Radiation Therapy: Results from the SPOTLIGHT study.
Presenter: Brian T. Helfand, MD, Chief of Division of Urology, NorthShore University HealthSystem, Evanston, Ill., on behalf of the SPOTLIGHT Study Group
Session Title: Prostate Cancer: Detection and Screening 1
Type: Moderated Poster MP40
Session Times: 1:00 – 3:00 PM CT
Abstract ID: 23-6028
Location: McCormick Place South Building, Room S405ab

Blue Earth Diagnostics invites participants at AUA2023 to attend the presentation above and to learn more about the Company at Booth 645.

Source: © Blue Earth Diagnostics. (2023). Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 SPOTLIGHT Study of PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer [Press release]. https://www.blueearthdiagnostics.com/news.